What are the recommended upper age limits for PSA screening in men and for average‑risk colonoscopy screening?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 23, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

PSA and Colonoscopy Screening: Upper Age Limits

Stop routine PSA screening at age 70 for most men, and discontinue colonoscopy screening at age 75 for average-risk individuals.

PSA Screening: When to Stop

Standard Stopping Age

  • Discontinue routine PSA screening at age 70 for the majority of men, as randomized trial evidence demonstrating mortality benefit extends only up to this age. 1, 2
  • The USPSTF and American College of Physicians both recommend against PSA screening in men aged 70 years and older. 2

Selective Continuation Beyond Age 70

  • Continue screening beyond age 70 only in exceptionally healthy men who meet ALL of the following criteria: 1, 2, 3
    • Minimal or no comorbidity
    • Prior history of elevated PSA values
    • Life expectancy >10–15 years
    • Strong patient preference after shared decision-making

Evidence Supporting Age 70 Cutoff

  • Men aged 75 years or older with PSA <3.0 ng/mL have only a 0.2% risk of dying from prostate cancer, making continued screening unnecessary. 2
  • The median age of death from prostate cancer is 80 years, and 75% of men with localized disease die of other causes rather than prostate cancer. 2
  • For men aged 60 with PSA <1 ng/mL, the risk of metastatic disease is only 0.5% and prostate cancer death is 0.2%, suggesting screening can safely stop in this low-risk group. 2

Risk-Stratified Approach for Men Aged 60–70

  • PSA <1.0 ng/mL at age 60: Consider stopping screening entirely, given the extremely low risk of clinically significant disease. 2
  • PSA 1.0–3.0 ng/mL: Continue screening every 2 years until age 70, then reassess based on health status. 2
  • PSA ≥3.0 ng/mL: Continue annual screening and close surveillance, potentially extending beyond age 70 if the patient is very healthy. 2, 3

Colonoscopy Screening: When to Stop

Standard Stopping Age

  • Discontinue routine colonoscopy screening at age 75 for average-risk individuals who have had adequate prior screening (defined as negative colonoscopy within 10 years or negative FIT/stool testing). [@Evidence not provided in studies—general medical knowledge applies@]

Selective Continuation Beyond Age 75

  • Consider screening up to age 85 only in individuals who: [@Evidence not provided in studies—general medical knowledge applies@]
    • Have never been screened or have inadequate prior screening
    • Are in excellent health with life expectancy >10 years
    • Have no significant comorbidities that would make colonoscopy high-risk

Key Principle: Life Expectancy Threshold

  • Both PSA and colonoscopy screening require at least 10–15 years of remaining life expectancy to realize any mortality benefit, as the time lag between detection and potential death from these cancers is substantial. 1, 2, 4

Common Pitfalls to Avoid

  • Continuing PSA screening beyond age 70 in men with limited life expectancy increases harms (false-positives, unnecessary biopsies, treatment complications) without providing benefit. 2, 4
  • Failing to account for baseline PSA values when deciding to stop screening: Men with consistently low PSA (<1.0 ng/mL) in their 60s can safely stop earlier than age 70. 2
  • Not having a shared decision-making conversation before stopping screening, especially in healthy men who may benefit from continued surveillance. 1, 4
  • Ignoring comorbidities: Men with significant heart disease, diabetes, COPD, or other life-limiting conditions should stop screening earlier, as they are unlikely to live long enough to benefit. 2

Algorithm for Deciding When to Stop PSA Screening

Age 60–69:

  • PSA <1.0 ng/mL → Consider stopping now 2
  • PSA 1.0–2.5 ng/mL → Continue every 2 years until age 70 2
  • PSA ≥2.5 ng/mL → Continue annually until age 70 2

Age 70:

  • Life expectancy <10 years OR significant comorbidity → Stop screening 2, 4
  • Excellent health + PSA ≥3.0 ng/mL + life expectancy >15 years → Consider continuing 2, 3

Age 75+:

  • Stop screening in all men except those in exceptional health with prior elevated PSA and documented >15-year life expectancy 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Age Recommendations for PSA Screening Initiation in Prostate Cancer

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Prostate Cancer Screening Guidelines for 65-Year-Old Males

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

Should community-wide routine prostate cancer screening be implemented, and for which age and risk groups is it appropriate?
What are the current Prostate-Specific Antigen (PSA) testing age-related guidelines?
At what age can a Prostate-Specific Antigen (PSA) check be started for a male patient with average risk and no significant family history of prostate cancer?
What criteria should be prioritized when choosing a screening test for prostate cancer, such as Prostate-Specific Antigen (PSA)?
What are the United States Preventive Services Task Force (USPSTF) recommendations for prostate cancer screening in men?
What medication adjustments and follow‑up plan are recommended for an adult female with recurrent major depressive disorder on fluoxetine 20 mg daily and trazodone 25‑50 mg nightly who now has worsening low mood, early‑morning awakenings at 3 am, obstructive sleep apnea treated with CPAP, elevated thyroid‑stimulating hormone, prediabetes, and pending pharmacogenomic testing?
What is the best medication to treat an adult with anxiety and insomnia who has no contraindications or serious medical problems?
What is the appropriate evaluation and management for a urine specimen that shows >10^4 CFU/mL gram‑negative bacilli with two distinct colony morphotypes?
What is the appropriate intervention for a 19‑month‑old girl who is near the gross‑motor developmental cutoff but otherwise age‑appropriate in all other screening domains?
What is the recommended treatment for herpes zoster (shingles) in an otherwise healthy adult, including antiviral therapy, pain management, and follow‑up care?
For an adult with mild‑to‑moderate internal or external hemorrhoids and no allergy or contraindication to topical steroids, how should I use a topical hemorrhoid cream (e.g., Preparation H® Hydrocortisone Cream with lidocaine or pramoxine) – what concentration, application frequency, and maximum duration – and when should I consider second‑line therapies?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.